Ozempic Lawsuit Updates
Last updated:
If you saw a story this week about someone who lost the sight in one eye after taking Ozempic or another GLP-1 shot, you may be wondering where the lawsuits stand. Nobody has been paid. No trial date has been set in any of the federal cases.
The biggest open question sits with one judge in Philadelphia. She heard five days of testimony in September and is now deciding whether the doctors and scientists hired by the injured people can testify at trial. Her answer will shape every stomach case.
If you took one of these shots and were later treated for a serious stomach problem or sudden vision loss, you can ask for a free case review. Whether that history supports a claim depends on which drug you took, what your records show, and the deadline in your state. Pick the one that fits:
Free and no obligation. Deadlines are set by your state and can be short. Submitting a review request does not create an attorney-client relationship.
Where things stand right now
The federal cases are split into two groups by injury. Judge Karen Spencer Marston handles both groups in the federal court in Philadelphia.
- Stomach and bowel cases: 4,022 as of September 1, 2026.
- Vision loss cases: 216 as of the same date.
Neither group has a settlement, a claims form, or a trial date. Novo Nordisk, which makes Ozempic and Wegovy, has said it is fighting the cases. Eli Lilly, which makes Mounjaro and Zepbound, has said patient safety is its top priority. Both companies deny that their drugs cause these injuries.
If you already have a lawyer, that lawyer can tell you where your own case sits. Nothing on this page changes what they have told you.
The judge heard from the experts in September
From September 14 through 18, 2026, Judge Marston held a five-day hearing in Philadelphia. Doctors and scientists hired by each side took the stand, and lawyers for the other side questioned them.
The hearing covered two questions that reach every stomach case.
- Can these drugs cause the stomach and bowel injuries people describe? The injured people's experts say they can. The drug companies' experts say the science does not show that the drugs cause those injuries.
- Did the label warn clearly enough? The drug companies argue the warnings were enough. They also argue that federal drug law blocks these claims, because the FDA approves what the label says.
The drug companies have asked the judge to bar the injured people's experts from testifying. They have also asked her to end the cases on the label question without a trial. Written arguments on both requests closed on August 7.
The judge has not ruled. The schedule posted on the court's website sets no date for a decision.
What her ruling could mean
If the judge lets the injured people's experts testify, the stomach cases move toward trials. If she keeps those experts out, many of the cases could end.
She has ruled against the injured people on a related question before. In August 2025 she required anyone claiming gastroparesis to back up the diagnosis with a gastric emptying study, a test that measures how long food takes to leave the stomach. In the same order she barred two of their experts from testifying on how gastroparesis is diagnosed. The main Ozempic page explains which tests the court accepts and why a copy of your result is worth keeping.
The ruling has not come, and your filing deadline keeps running while everyone waits. Each state sets its own deadline. A free review can look at which shot you took, what your records show, and how much time your state allows.
Request a Free Case ReviewThe vision loss cases in the news
Starting September 21, several news outlets ran stories about people who say a GLP-1 shot cost them the sight in one eye. The condition is called NAION. Blood flow to the nerve behind the eye drops, and sight in that eye fades, often within a day. It usually does not come back.
The vision cases have their own group in federal court. The group was created in December 2025, and by September 1, 2026, it held 216 cases. Judge Marston handles these cases too.
The vision cases are at an early stage. In a July 2 order, the judge picked two questions to decide first. The first is whether these drugs can cause NAION at all. The second is whether federal drug law and the existing label block the claims. On August 27 she set the schedule for getting there.
- September 25, 2026: the two sides propose the questionnaire each person suing will later fill out about their use of the drug and their diagnosis.
- October 28, 2026: the injured people's lawyers file one shared complaint for the whole group.
- December 18, 2026: the deadline to finish collecting records and testimony from Eli Lilly.
- February 26, 2027: the same deadline for Novo Nordisk.
- March through June 2027: each side's experts write their reports, then answer questions under oath.
- July 2 through August 31, 2027: written arguments over whether those experts can testify and whether the cases should end without a trial.
The judge will rule on those two questions after the last written arguments come in on August 31, 2027.
Regulators in Europe and the United States have handled the risk differently. In June 2025 the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide, the drug in Ozempic, Wegovy and Rybelsus. Very rare means it affects up to 1 in 10,000 people. The current U.S. Ozempic label, revised in May 2026, tells patients to report changes in their vision to their doctor. The U.S. label does not name NAION.
If you are taking one of these shots and your vision changes, call your doctor. Whether to keep taking the drug is a question for the doctor who prescribed it.
People are still filing
New cases keep arriving. The stomach group held about 1,000 cases two years ago and 4,022 on September 1, 2026. Through 2026 it has added roughly 80 to 90 cases a month. The vision group reached 216 cases in its first nine months. On September 18 the court moved one more vision case into the group, a Georgia case against Novo Nordisk.
Some people have also withdrawn their cases. On September 8 the judge closed 59 stomach cases after the people who filed them asked to dismiss them. The order does not give their reasons.
A rising count tells you how many people have sued. Your own case turns on your records, the drug you took, and your state's deadline. Each state sets its own filing deadline, and that clock keeps running whether or not the judge has ruled.
Waiting for the ruling does not pause your deadline. A free review can check your dates against the deadline in your state.
Get a Free Ozempic Case ReviewWhat to watch next
- The judge's ruling on the September hearing. No date has been set.
- The next federal case count. The Judicial Panel on Multidistrict Litigation posts one on the first business day of each month, so the October count should appear on October 1.
- The first two deadlines in the vision loss cases, on September 25 and October 28.
- The next status conference in the vision loss cases, set for October 13.
- Any change to the U.S. label on vision loss.
This page gets rewritten when any of those happen. The main Ozempic page carries the background that stays the same from month to month.
How this page fits with the main Ozempic page
This page tracks what is happening in court. The main Ozempic and Wegovy lawsuits page explains which shots the cases name, what injuries people report, and which records to keep. If you are new to this, start there and come back here for the current status. For the research behind the stomach and vision claims, see does Ozempic cause gastroparesis.
Sources
- Judicial Panel on Multidistrict Litigation, pending MDL report of September 1, 2026 (PDF). Lists 4,022 actions in MDL 3094 and 216 in MDL 3163.
- Judicial Panel on Multidistrict Litigation, Pending MDLs. A new report is posted on the first business day of each month.
- MDL 3094 scheduling order for the Rule 702 hearing, entered August 28, 2026 (PDF). Sets the hearing for September 14 through 18, 2026.
- MDL 3094 Case Management Order No. 32, entered April 30, 2026 (PDF). Sets the briefing schedule for the expert and summary judgment motions, with the last reply due August 7, 2026.
- MDL 3094 Case Management Order No. 18 (PDF). Defines the court-wide questions, including label adequacy and federal preemption (issue 2) and general causation (issue 3).
- Docket of In re: GLP-1 RAs Products Liability Litigation, MDL No. 3094, No. 2:24-md-03094-KSM (E.D. Pa.), available through PACER. The hearing minute entries are ECF Nos. 887 through 891. The September 8, 2026 order closing 59 voluntarily dismissed cases is ECF No. 883.
- Eastern District of Pennsylvania, orders in MDL 3094. Includes the August 15, 2025 memorandum order requiring a gastric emptying study (ECF No. 468).
- MDL 3163 Case Management Order No. 12, entered July 2, 2026 (PDF). Puts general causation and preemption first in the vision loss cases.
- Docket of In re: GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, No. 2:25-md-03163-KSM (E.D. Pa.), available through PACER. Case Management Order No. 14, entered August 27, 2026 (ECF No. 149), sets the deadlines listed above. The status conference schedule is the order of April 30, 2026 (ECF No. 86), and the September 18, 2026 transfer order is ECF No. 156.
- European Medicines Agency, June 2025 conclusion on NAION and semaglutide.
- FDA, Ozempic prescribing information, revised May 2026 (PDF).
- Gray Media, “Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss,” September 22, 2026. Source of the company statements quoted above.
Find Out If You May Have a Case
If you took Ozempic, Wegovy, Mounjaro or another shot in this group and were later treated for a serious stomach problem or for sudden vision loss, a free case review can look at which drug you took, what your records show, and the filing deadline in your state.
Free and no obligation. Lawsuit Center is not a law firm and submitting a request does not create an attorney-client relationship.
